Arrowhead Pharma starts price war with Ionis

Arrowhead Pharmaceuticals' RNAi drug plozasiran, brand name Redemplo, is now the second FDA-approved therapy for familial chylomicronemia syndrome, an inherited lipid disorder. Beyond its claims of safety and dosing advantages, Arrowhead set a dramatically lower price for its first commercial product, which will compete against an Ionis Pharmaceuticals drug.

Editor's Pick

Top Story With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis Arrowhead Pharmaceuticals' RNAi drug plozasiran, brand name Redemplo, is now the second FDA-approved therapy for familial chylomicronemia syndrome, an inherited lipid disorder. Beyond its claims of safety and dosing advantages, Arrowhead set a dramatically lower price for its first commercial product, which will compete against an Ionis Pharmaceuticals drug. Sponsored Leading ABA Therapy Centers: A Comparison Presented by Arms Wide Open ABA Health care professionals can learn more about the top-rated ABA therapy providers in New Hampshire to understand where their patients can get help from industry leaders. Learn More

Featured News

The Power of One: Redefining Healthcare with an AI-Driven Unified Platform   [Sponsored] In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation. Pyx Health Introduces Platform to Support Those Affected by OBBBA Pyx Health launched an AI-driven platform to help members navigate care, meet new Medicaid and SNAP requirements and address social needs like food insecurity. Addressing Operational Inefficiencies in Healthcare Finance to Drive Better Business Decisions Fragmented finance systems have long caused operational challenges. By addressing this, CFOs can optimize and streamline many finance processes to improve compliance readiness and create time for business-driven decisions that support business objectives.

Video   Video: Looking for smarter health guidance? Carolyn Jasik from Verily talks about their telemedicine app linking users to licensed doctors and Violet, an AI that answers your health questions using your own medical records. Watch the interview to see how Verily is changing health access.

Sponsored 5 High-Impact Tax Strategies Every Physician Should Use in 2026 to Reduce Their Tax Bill Presented by Gelt AI-native tax firm Gelt combines top human tax experts with AI to help physicians and healthcare practices use data-driven tax strategies to lower liabilities, improve profitability, and future-proof their finances. Learn More

Resources

MedCity FemFwd: Inside Wellcome Leap and Pivotal's $100M Commitment To Women's Health In this episode, we're joined by Dr. Renee Wittemyer, vice president of program strategy at Pivotal Ventures, and Dr. Regina Dugan, CEO of Wellcome Leap. They discuss the organizations' recent $100 million commitment to accelerate women's health research. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe